FDA's Fertility & Maternal Health Drugs Advisory Panel
Executive Summary
On the first day of its April 27-28 meeting, the committee will discuss the NDA for the slow release, subcutaneous contraceptive capsule Norplant (levonorgestrel). The Population Council, New York City, is the sponsor of the application. The following day, the panel will review Syntex' NDA for nafarelin acetate for treatment of endometriosis. The meeting will be held in conference room G in FDA's Parklawn Building.